On December 4, 2023 Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that the Company will host an in-person investor event, along with a live webcast, on Monday, December 11, 2023, at 7:00 a.m. PT / 10:00 a.m. ET during the 65th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in San Diego, California (Press release, Syndax, DEC 4, 2023, View Source [SID1234638134]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will include new data for both the axatilimab and revumenib programs, and members of the Syndax management team will be joined by the following key opinion leaders:
Daniel Wolff, M.D., Professor of Hematology, Department of Internal Medicine III of the University of Regensburg
Eytan M. Stein, M.D., Chief, Program for Drug Development in Leukemia, Department of Medicine, Memorial Sloan Kettering Cancer Center
Ghayas C. Issa, M.D., Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Joshua F. Zeidner, M.D., Associate Professor of Medicine, Chief, Leukemia Research, University of North Carolina, Lineberger Comprehensive Cancer Center
Neerav N. Shukla, M.D., Chief, Pediatric Translational Medicine Service, Memorial Sloan Kettering Cancer Center
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website or directly through the meeting link here.
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company’s website at www.syndax.com for a limited time.